According to NCCN guidelines, dual checkpoint blockade utilizing PD-1/PD-L1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors is endorsed as a category 1 treatment for metastatic NSCLC [93]. Here, CTLA4 is linked to non-small cell lung carcinoma.